Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NeuroEPO in Mild to Moderate Alzheimer's Disease
NCT07178678Phase 2Not yet recruiting
- Sponsor
- University of Saskatchewan
- Start
- Nov 2025
- Primary completion
- Mar 2030
- Modality
- Inhalation Devices, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of NeuroEPO in Alzheimer's disease (AD), sponsored by University of Saskatchewan. Planned start Nov 2025; status: not yet recruiting.
02
Drugs
NeuroEPO
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT07178678.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07178678.